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The autoantibodies in autoimmune hepatitis (AIH) are extensively used for its diagnosis and
classification. However, they are also useful for defining the prognosis and inferring clinical
behavior.
For the Diagnosis and Classification of AIH
In accordance with the classical criteria for the diagnosis of AIH, the importance of autoantibody
testing is diluted among 12 parameters (1). Only adult patients with autoantibody reactivity
greater than 1/80 for the classical markers, such as anti-smooth muscle antibodies (ASMAs), anti-
nuclear antibodies (ANAs), and anti-liver/kidney microsome type 1 (anti-LKM1) antibodies, score
three points. When these markers are absent, other secondary antibodies, such as anti-soluble
liver/pancreas antigen (anti-SLA/LP) and liver cytosol type 1 (anti-LC1), should be tested. It is
possible to reach a definite diagnosis of AIH without any autoantibody reactivity, and this occurs in
approximately 5–10% of all AIH cases.
Further, a simplified scoring system was proposed based on only four parameters: absence of
viral hepatitis antibodies, increased IgG levels, typical histological features, and reactivity for liver
autoantibodies (each with a maximum score of two points under standard specifications) (2). As
stated in the interpretation of these simplified criteria, it is impossible to have a definite diagnosis
without any reactivity for autoantibodies, and we know this is not true.
The reactivity of autoantibodies in AIH is crucial for its classification. ASMAs and ANAs are
markers of type 1 AIH (AIH-1), and anti-LKM1 and anti-LC1 antibodies are markers of type 2
AIH (AIH-2). Anti-SLA/LP antibodies were initially considered markers of a third type of AIH, but
this subject is still under debate. The major autoantibodies, their corresponding target antigens, the
techniques for their detection, and the main features of AIH that they are the markers are displayed
in Table 1.
Anti-Smooth Muscle Antibodies/Antimicrofilament Antibodies/Anti-Actin
Antibodies
Anti-smooth muscle antibodies were initially described in rodent stomach sections in 1965, with
reactivity in theMuscularis mucosae, the submucosa vessel walls, and the muscular layers. However,
the patterns observed in kidney sections yield more information because the target antigen for
ASMAs is the filamentous form of actin (F-actin), and this information is provided via the presence
of a tubular pattern (a fluorescent reaction in the vessels, glomeruli and fibrils inside the tubular cells
in unfixed rodent kidney sections, Figures 1A,B) (9).
To properly detect anti-F-actin antibodies by indirect immunofluorescence, it is necessary to iden-
tify the reactivity ofmicrofilaments in cell culture (Figure 1C). To better visualize themicrofilaments
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TABLE 1 |Main autoantibody markers of AIH with their corresponding target antigens, techniques of detection, and AIH clinical features (1, 3–8).
Autoantibodies Target antigen Techniques of detection AIH clinical features
Anti-smooth muscle antibodies
(ASMA)
Filamentous actin IIF – rodent stomach and kidney
sections – reaction on stomach muscular layers,
vessels, glomeruli, and fibrils of tubular cells
(tubular pattern)
Ratio female: male – 4:1




The most common marker of
AIH in all ages
HLA susceptibility DR3 and, North and
South America countries with DR13
Anti-actin antibodies Filamentous actin IIF – cell culture (human fibroblasts, HEp2 cells)
ELISA (less specific); high reactivity in other liver
diseases and even without ASMA reactivity
Anti-nuclear antibodies (ANA) Histone, Ro (SSA) IIF (homogeneous and speckled patterns) Isolated ANA are more common in adults
50–70% of patients with AIH-1,
mainly in association with ASMA
Other patterns (nucleolar, centromere, nuclear
dots, and nuclear envelope) are not related to AIH
Markers of a less aggressive disease
Higher association with rheumatologic
diseasesELISA (anti-histone and anti-Ro antibodies)
Relationship with HLA DR4; in Brazil there
is no relationship between ANA reactivity
and HLA DR
Anti-liver kidney microsome
antibodies type 1 (anti-LKM1)
15% of patients with AIH
90% of patients with AIH-2
Cytochrome CYPIID6 IIF – liver and kidney tissue
sections – homogeneous fluorescence in
hepatocytes, and reactivity in proximal renal
tubular cells
AIH-2
More frequently detected in young children,
even younger than 5 years old; less
commonly in patients older 20 years of age
Immunoblotting (mainly 50, 56, and 66 kDa) Acute liver failure
Other techniques: immunodiffusion, ELISA, LIA Relationship with class II HLA DR7 and
DQ2 (Brazil and Canada); DR3 (Western
Europe)
Relapses more frequent
Anti-liver cytosol type 1 Formiminotransferase
cyclodeaminase
IIF (when anti-LKM1 antibodies are negative) Few studies with patients carrying these
antibodies without anti-LKM1
More severe and less responsive to
treatment forms of AIH
30–40% of patients with AIH-2;
only 10% of AIH-2 patients with
these antibodies alone
Homogenous reactivity in hepatocytes, with
fading fluorescence reactivity around centrilobular
venules; no reactivity in proximal tubules
More frequently in association
with anti-LKM1
Immunoblotting: 62 kDa with liver antigen sources
Other techniques: immunodiffusion, ELISA
Anti-soluble liver/liver pancreas
antibodies (anti-SLA/LP)
One-third of patients with AIH





ELISA, immunoblotting, line immunoassay
No reactivity by IIF
More relapses after treatment withdrawal
90% reactivity together with anti-RO 52
antibodies)
High association with HLA DR3
Higher levels of γglobulinsMore frequently detected in
AIH-1 than AIH-2
15–20% of all AIH patients
AIH, type 1 autoimmune hepatitis; AIH-2, type 2 autoimmune hepatitis; ASMA, anti-smooth muscle antibodies; ANA, antinuclear antibodies; anti-LKM1, anti-liver kidney microsome
antibodies type 1; Anti-SLA/LP: anti-soluble liver/liver pancreas antibodies; IFI: indirect immunofluorescence.
in cells in lower dilutions, one must heat inactivate the
serum samples at 56°C for 30min or dilute them in calcium
chelating solutions to inactivate a serum labile and calcium-
dependent protein that severs F-actin from the substrate, called
gelsolin (10).
The vascular and glomerular patterns of ASMAs are fre-
quently seen in other clinical conditions and frequently in lower
titers. The antigenic specificity in this situation usually is for
other components of the cytoskeleton, such as vimentin, desmin,
tubulin, or cytokeratin. These anti-cytoskeleton autoantibodies
are more easily observed when the cells are treated with vin-
blastine or colchicine. Sometimes, it is important to choose
a specific type of cell culture because the intermediate fila-
ments are not the same for all cell types. International diagnos-
tic scoring systems make no specification for ASMA patterns,
and a vascular/stomach pattern higher than 1/80 has the same
meaning of a tubular pattern higher than 1/320, which is not
definitely true.
There is a commercially available anti-F-actin ELISA, and we
tested this assay in different patient groups with liver diseases.
The AIH-1 group in which only patients with ASMAs with the
tubular pattern and with F-actin specificity were included had the
highest reactivity frequency. Almost, all patients demonstrated
reactivity according to this assay. However, the control groups
also demonstrated a high reactivity frequency, even when the cut
off was shifted up 4 SDs, which differed from the manufacturer’s
recommendations. Furthermore, even patients without reactivity
to ASMAs had some reactivity according to this assay. Thus, it is
uncertainwhether this commercial ELISA always detects the same
antigen as indirect immunofluorescence. For this reason, although
highly related to the tubular pattern of ASMAs (11), we still do not
recommend this assay for routine examinations.
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FIGURE 1 | Upper panel: Anti-smooth muscle and anti-microfilaments
antibodies in type 1 autoimmune hepatitis. (A) ASMA in rat stomach sections;
(B) the tubular pattern of ASMA in rat kidney sections; (C) anti-microfilament
and antinuclear antibodies in human fibroblasts. Lower panel: Anti-liver
kidney microsome antibodies type 1 (anti-LKM1) and anti-liver cytosol
antibodies type 1 (anti-LC1) in type 2 autoimmune hepatitis; (D) anti-LKM1 in
rat liver sections; (E) anti-LKM1 in rat kidney sections; (F) anti-LC1 in rat liver
sections.
Anti-Nuclear Antibodies
The two more common patterns of ANAs detected in AIH are
the homogeneous and speckled. However, often it turns out to
be an association of patterns. Sometimes, the pattern changes
during the course of treatment or even during the process of serum
titration. When antigenic specificities are tested, histone H1 and
SSA/RO are the most prevalent target antigens. Frequently, ANAs
are detected together mainly with ASMAs but also with anti-
LKM1, anti-LC1, and anti-SLA/LP antibodies, all of them more
specific for AIH. In this situation, the type of AIH that the patient
should be classified as is not clear.
Although the ANA detection is universally performed using
HEp2 cells as substrate, a review of the International Group of
AIH suggestedHEp2 cells should not be used initially as screening
because of the high positivity rate in lower dilutions (less than
1/80), and for children the reactivity in those dilutions is useful
in characterizing AIH subtypes (1, 3).
An unresolved issue on the reactivity of the ANA is that there
is no specification for patterns in the diagnostic scoring systems.
Both international scoring systems for the diagnosis of AIH score
points for ANA reactivity in the presence of centromeric, nucle-
olar, nuclear dots and nuclear envelope patterns, even in the
presence of rheumatic diseases that, per se, justify their presence.
Only homogeneous and speckled patterns should be considered
AIH markers.
Anti-Liver Kidney Microsome Antibodies Type 1
and Anti-Liver Cytosol Antibodies Type 1
Anti-LKM1 and anti-LC1 antibodies are the primary markers
of AIH-2. Their target antigens are the enzymes cytochrome
CYP2D6 and formiminotransferase cyclodeaminase, respectively.
Anti-LKM1 antibodies are characterized by reactivity in proximal
renal tubules in the renal cortex and by a diffuse reaction in
hepatocytes in rat tissue sections. Anti-LC1 antibodies are char-
acterized by reactivity in hepatocytes with a weak fluorescence
around the centrilobular veins without any reactivity in renal
tubules (Figures 1D–F). Anti-LC1 antibodies are only detected
by indirect immunofluorescence if anti-LKM1 antibodies are not
present simultaneously. Both antibodies are also determined using
purified rat and human liver antigens by immunoblotting and
immunodiffusion and by ELISA and line immunoassay using
recombinant antigens. By immunoblotting with rat antigens, anti-
LKM1 antibodies are depicted in three bands of 50, 56, and
66 kDa. The 50 kDa band is the most important. For anti-LC1,
only one 62 kDa band is observed when using human antigens.
Anti-LKM1 antibodies aremarkers in 90%of patients withAIH-2,
while anti-LC1 in 25–40% of patients, more frequently in associa-
tion with anti-LKM1. Anti-LC1 antibodies alone are markers for
approximately 10%of patientswithAIH-2.Anti-LKM1antibodies
are detected in <5% of patients with chronic hepatitis C; anti-LC1




Anti-SLA/LP antibodies were initially described in 1981 with the
name anti-liver pancreas, and in 1987 as anti-SLA antibodies. The
target antigen of anti-SLA/LP is Sep (O-phosphoserine) tRNA: Sec
(selenocysteine) tRNA synthase (12), named SepSecS according
to the Nomenclature Commission of the Human Genome Orga-
nization. The enzyme SepSecS catalyzes the last step of seleno-
cysteine synthesis. These antibodies can be detected by ELISA,
immunoblotting, radioligand assay, and line immunoassay using
purified or recombinant antigens.
In a multicenter study from Germany, USA, Japan, and Brazil,
the reactivity of anti-SepSecS was approximately 15% when con-
sidering patients with AIH, and was approximately 30% when
considering AIH without the classical markers (4). Close to 10%
of patients with chronic hepatitis C exhibited these markers. In
our institution, anti-SepSecS reactivity was present in 33% of
patients withAIHwithout the classicalmarkers; in 23%of patients
with type 1 AIH; and 13% of patients with type 2 AIH. Overall,
22% of 243 patients with AIH were positive compared to only
4% of 151 controls that included patients with chronic hepatitis
C with autoimmune features, primary biliary cirrhosis, primary
sclerosing cholangitis, celiac disease, and healthy individuals.
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In a review of adult and pediatric patients from our hospital, we
determined the distribution of AIH subtypes. From 227 patients
with AIH, 78% of 177 patients had AIH-1; 47% had ASMAs; 16%
had isolated ANAs; and 37% had both markers. Ninety percent of
patients with ASMA reactivity demonstrated specificity for anti-
microfilament antibodies. Fourteen percent of 32 patients had
AIH-2; 75% with isolated anti-LKM1 antibodies; 9% with isolated
anti-LC1 antibodies; and 16% with both markers. Hence, 90% of
patients with AIH-2 had anti-LKM1 antibodies. Eight percent of
the whole cohort of AIH patients demonstrated no reactivity for
the classical markers, and one third of them tested positive for
anti-SepSecS antibodies (5).
For Defining the Prognosis or Inferring the
Clinical Features and Behavior of AIH
Patients with anti-LKM1 reactivity are usually younger than
patients with other autoantibody profiles, and patients with anti-
SepSecS or with isolated ANA reactivity tend to be older (4, 6).
AIH-2 is usually more aggressive, and acute liver failure is more
common in these patients. Patients with AIH-2 exhibited an IgA
deficiencymore frequently; on the other hand, the levels of gamma
globulin and IgG are considerably higher in patients with anti-
microfilament and anti-SepSecS antibodies than in patients with
anti-LKM1 (4–6).
Patients with anti-LC1, anti-SepSecS, and anti-F-actin antibod-
ies have a worse prognosis than their counterparts with isolated
ANAs in which the response to treatment is much better than
in patients with other serological markers (13, 14). Those who
remain reactive to anti-F-actin greater than 1/40 and to ASMA
greater than 1/80 after treatment usually have histological activ-
ity (15). Patients with reactivity for anti-SepSecS have relapses
more frequently than other patients after treatment withdrawal.
However, the prognostic implications ascribed to these antibodies
could also be related to anti-Ro52 reactivity due to the almost
invariable concomitance of these two types of autoantibodies (7).
One of the explanations for the clinical differences among
patients with AIH is related to their genetic background according
to MHC class II. In Western Europe and North America, AIH-1
has a primary association with HLA DR3 and a secondary associ-
ation with HLADR4. In contrast, HLADR4 is the primary associ-
ation in Japan and Mexico. For AIH-2, the primary association is
HLA DR3 in Europe and HLA DQ2 and HLA DR7 in Canada.
AIH-1 in South America (Argentina, Brazil and Venezuela) is
related to HLA DR13, but only in Brazil, this susceptibility was
related to anti-microfilament antibody reactivity (8). In Brazilian
patients, for AIH-2 the susceptibility was related to HLA DR7,
for patients with anti-SepSecS reactivity to HLA DR3 (like in
other countries), and for patients with isolated ANA reactivity no
specific association with class II alleles was observed.
Conclusion
In summary, in AIH, there is no need to test the entire panel
of autoantibodies. The presence of one is sufficient to facilitate
the diagnosis, and the treatment is the same regardless of the
serological markers. It is important to highlight that the reactivity
of autoantibodies is one of the several important parameters to
diagnose AIH, as are the high levels of gamma globulins; the
typical histological alterations; the therapeutic response to corti-
costeroids and azathioprine; and the relapse after discontinuation
of treatment. On the other hand, the diagnosis can be made even
without any serological markers. However, to deeply understand
the patients, at least, five autoantibodies (ASMA, anti-LKM1, anti-
LC1, ANA, and anti-SepSecS) should be tested with the hope
of explaining the clinical manifestations, biochemical changes,
genetic background, clinical course and treatment response and,
perhaps, of identifying a triggering agent.
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